TY - JOUR
T1 - Carbapenem Antibiotics
T2 - Recent Update on Synthesis and Pharmacologi-cal Activities
AU - Tiwari, Abhishek
AU - Tiwari, Varsha
AU - Sahoo, Biswa Mohan
AU - Banik, Bimal Krishna
AU - Kumar, Manish
AU - Verma, Navneet
N1 - Publisher Copyright:
© 2023 Bentham Science Publishers.
PY - 2023/3
Y1 - 2023/3
N2 - Right from the breakthrough of carbapenems since 1976, many schemes on synthe-sis, structure-activity relationship (SAR), and biological activities have been carried out, and several carbapenems have been developed, including parentally active carbapenems like imipenem, doripenem, biapenem, meropenem, ertapenem, panipenem, razupenem, tomopenem, and cilastatin, whereas orally active carbapenems like GV-118819, GV-104326, CS-834, L-084, DZ-2640, CL 191, 121, L-646, 591, S-4661, ER-35768, MK-826. Prodrugs of carbapenem with increased bioavailability include temopenem, tebipenem, sanfetrinem, LK-157, and CP 5484. Merck, Glaxo Welcome Research Group, Johnson & Johnson, Sankyo Group and Dai-ichi Group, and Wyeth-Ayerst Group were among the businesses that produced carbapenems. In this review Witting reaction, Mitsunobu reaction, Dieckmann reaction, palladium-catalyzed hydro-genolysis, E. coli-based cloned synthesis, as well as biosynthetic enzymes such as carbapenem synthetase (carA), carboxymethylproline synthase (carB), carbapenem synthase (carC) are in-cluded. Carbapenems are biologically mainly active in the infections like urinary tract infec-tions, bloodstream infections, tuberculosis, intra-abdominal infections, and pathogens like an-aerobes, gram-positive and gram-negative bacteria.
AB - Right from the breakthrough of carbapenems since 1976, many schemes on synthe-sis, structure-activity relationship (SAR), and biological activities have been carried out, and several carbapenems have been developed, including parentally active carbapenems like imipenem, doripenem, biapenem, meropenem, ertapenem, panipenem, razupenem, tomopenem, and cilastatin, whereas orally active carbapenems like GV-118819, GV-104326, CS-834, L-084, DZ-2640, CL 191, 121, L-646, 591, S-4661, ER-35768, MK-826. Prodrugs of carbapenem with increased bioavailability include temopenem, tebipenem, sanfetrinem, LK-157, and CP 5484. Merck, Glaxo Welcome Research Group, Johnson & Johnson, Sankyo Group and Dai-ichi Group, and Wyeth-Ayerst Group were among the businesses that produced carbapenems. In this review Witting reaction, Mitsunobu reaction, Dieckmann reaction, palladium-catalyzed hydro-genolysis, E. coli-based cloned synthesis, as well as biosynthetic enzymes such as carbapenem synthetase (carA), carboxymethylproline synthase (carB), carbapenem synthase (carC) are in-cluded. Carbapenems are biologically mainly active in the infections like urinary tract infec-tions, bloodstream infections, tuberculosis, intra-abdominal infections, and pathogens like an-aerobes, gram-positive and gram-negative bacteria.
KW - Carbapenem
KW - antibiotics
KW - chemistry
KW - mechanism of action
KW - resistance
KW - structure
UR - http://www.scopus.com/inward/record.url?scp=85146188681&partnerID=8YFLogxK
U2 - 10.2174/2589977514666220907141939
DO - 10.2174/2589977514666220907141939
M3 - Artículo de revisión
C2 - 36082853
AN - SCOPUS:85146188681
SN - 2589-9775
VL - 15
SP - 35
EP - 61
JO - Current Drug Research Reviews
JF - Current Drug Research Reviews
IS - 1
ER -